Intensity Therapeutics, Inc.已重新启动其针对三阴性乳腺癌的随机、术前二期临床试验的患者治疗工作。该试验代号为Invincible-4研究，旨在评估公司核心治疗方案在手术前治疗阶段的有效性与安全性。此次重启标志着临床试验进程步入关键阶段，为后续数据收集与分析奠定了重要基础。研究设计的随机性与术前干预特点，有望为三阴性乳腺癌这一治疗需求迫切的领域提供新的临床证据。公司方面表示，将严格遵循试验方案推进患者入组与治疗，并密切监测相关临床指标。
Intensity Therapeutics, Inc.已重新启动其针对三阴性乳腺癌的随机、术前二期临床试验的患者治疗工作。该试验代号为Invincible-4研究，旨在评估公司核心治疗方案在手术前治疗阶段的有效性与安全性。此次重启标志着临床试验进程步入关键阶段，为后续数据收集与分析奠定了重要基础。研究设计的随机性与术前干预特点，有望为三阴性乳腺癌这一治疗需求迫切的领域提供新的临床证据。公司方面表示，将严格遵循试验方案推进患者入组与治疗，并密切监测相关临床指标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.